Report Overview
The EU DPP-4 inhibitors market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of 4.9% during the forecast period
DPP-4 inhibitors are important oral antidiabetic agents that are placed as second-line therapy after metformin failure as insulin tropic agents that have no intrinsic hypoglycemia risk and are body weight neutral. Under hyperglycemic conditions they additionally inhibit glucagon secretion
Market Drivers
The market is directly proportional to the growing type 2 diabetic population. In most of the cases, DPP-4 are the second line of drugs prescribed for type 2 patients. Over the years, the European diabetic population increased tremendously, and type 2 population accounts for almost 90% of the diabetic population. The growth in diabetic population is due to it being a lifestyle disease
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.